Table 1.
Baseline |
Treatment |
ANOVA |
Post-hoc comparisons |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pramipexole |
Placebo |
Pramipexole |
Placebo |
Baseline vs. Treatment |
Pramipexole vs. Placebo |
||||||||||
Mean | SD | Mean | SD | Mean | SD | Mean | SD | Night | Group | Night×Group | Pramipexole | Placebo | Baseline | Treatment | |
TIB, min | 504.2 | 96.16 | 514.5 | 83.99 | 518.4 | 43.40 | 481.2 | 91.21 | N.S. | N.S. | N.S. | ||||
SPT, min | 466.7 | 98.82 | 480.3 | 82.86 | 490.7 | 48.43 | 453.4 | 88.63 | N.S. | N.S. | N.S. | ||||
TST, min | 332.4 | 118.99 | 397.3 | 92.01 | 407.4 | 62.14 | 365.8 | 79.39 | N.S. | N.S. | 0.009 | ||||
SL, min | 26.0 | 30.76 | 21.9 | 22.38 | 17.6 | 22.64 | 17.5 | 20.62 | N.S. | N.S. | N.S. | ||||
RL, min | 117.2 | 89.95 | 96.8 | 39.26 | 133.8 | 88.29 | 120.6 | 63.38 | N.S. | N.S. | N.S. | ||||
SS/hour | 11.2 | 4.58 | 12.6 | 4.10 | 13.4 | 4.28 | 12.2 | 4.09 | N.S. | N.S. | N.S. | ||||
AWN/hour | 4.9 | 2.68 | 4.3 | 2.55 | 5.7 | 3.26 | 4.2 | 2.38 | N.S. | N.S. | N.S. | ||||
SE% | 65.2 | 19.36 | 77.1 | 11.10 | 78.7 | 10.41 | 76.6 | 11.53 | 0.035 | N.S. | 0.025 | 0.0008 | N.S. | ||
WASO, % | 30.0 | 18.84 | 17.3 | 12.38 | 17.0 | 9.05 | 18.6 | 12.27 | 0.1>P>0.05 | N.S. | 0.02 | ||||
S1, % | 6.3 | 6.02 | 6.7 | 4.04 | 5.3 | 4.74 | 5.9 | 4.57 | N.S. | N.S. | |||||
S2, % | 38.0 | 10.79 | 43.6 | 10.65 | 49.9 | 12.00 | 44.7 | 10.32 | 0.008 | N.S. | 0.03 | 0.0002 | N.S. | ||
SWS, % | 13.7 | 8.32 | 15.3 | 8.92 | 15.6 | 7.50 | 16.2 | 5.94 | N.S. | N.S. | N.S. | ||||
REM, % | 12.1 | 7.91 | 17.1 | 5.23 | 12.2 | 4.82 | 14.6 | 4.54 | N.S. | 0.005 | N.S. | 0.007 | N.S. |
TIB, time in bed; SPT, sleep period time; TST, total sleep time; SL, sleep latency; RL, REM latency; SS, stage shifts; AWN, awakenings number; SE, sleep efficiency; WASO, wakefulness after sleep onset; S1, stage 1; S2, stage 2; SWS, slow wave sleep; REM, REM sleep.